Technology | Interventional Radiology | May 23, 2018

Guerbet Launches Pair of Microcatheters for Interventional Radiology Procedures

SeQure and DraKon microcatheters are now available for use in image-guided embolization procedures

Guerbet Launches Pair of Microcatheters for Interventional Radiology Procedures

May 23, 2018 — Guerbet LLC USA announced the upcoming launch of SeQure and DraKon, two novel microcatheters for tumor and vascular aneurysm embolization procedures. The company introduced the microcatheters at the Global Embolization Symposium and Technologies (GEST) 2018 U.S., May 17-20 in Miami.

SeQure and DraKon microcatheters received U.S. Food and Drug Administration (FDA) clearance on Jan. 26, 2018, for the use of infusion media into all peripheral of contrast vessels as well as drug infusion in intra-arterial therapy and infusion of embolic materials.

SeQure is designed to lower the risk of non-targeted embolization with its fluid barrier technology. The catheter has a unique filter tip designed to increase drug and embolic microsphere delivery to tumors, reducing embolic material backflow for enhanced and targeted embolization

DraKon is a standard microcatheter adapted for conventional transarterial chemoembolization (c-TACE) as well as simple embolization cases.

Both SeQure and DraKon offer enhanced intra-arterial navigation to interventional radiologists, with optimal combination of torqueability, pushability, trackability and visibility, and kink resistance. This enables access in cases of difficult-to-navigate vascular networks and lesions.

Some examples of use may include:

  • Vascular tumors and anomalies requiring treatment with catheter embolization, such as liver cancer directed therapies including cTACE and drug-eluting bead TACE (DEB-TACE);
  • Renal and lung tumor embolization;
  • Pre-operative embolization of cancer tumors;
  • Pre-surgical embolization of juvenile angiofibroma;
  • Uterine fibroid embolization;
  • Prostatic artery embolization for benign prostatic hyperplasia;
  • Angiomiolipomas;
  • Hemorrhages; and
  • Vascular anomalies.

Guerbet obtained both microcatheters in their acquisition of Israeli company Accurate Medical Therapeutics announced in January 2018.

SeQure and DraKon will be available for sale during the third quarter of 2018.

For more information: www.guerbet.com


Additional Content

News | Cath Lab

Nov. 2, 2026 — Royal Philips has announced U.S. commercial availability of the HyperVue Integrated System1, a new single ...

Home November 03, 2026
Home
News | Cath Lab

Aug. 28, 2026 — Heartflow, Inc. has announced late-breaking one-year results from an independent randomized clinical ...

Home August 28, 2026
Home
News | Cath Lab

July 9, 2026 — On July 9, Stereotaxis announced that it has completed its previously announced acquisition of Robocath ...

Home July 10, 2026
Home
News | Cath Lab

June 18, 2026 — Allegheny Health Network's (AHN) Allegheny General Hospital (AGH) has completed a $19 million renovation ...

Home June 18, 2026
Home
News | Cath Lab

May 28, 2026 — RWJBarnabas Health has earned Cardiac Catheterization Lab Accreditation from the American College of ...

Home May 29, 2026
Home
Subscribe Now